What is riociguat, and what is it used for?
Riociguat is a medicine that stimulates soluble guanylate cyclase, which helps increase blood levels of cyclic GMP and improves blood vessel signaling. It is used to treat specific pulmonary vascular diseases, including pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). [1]
How does riociguat work in the body?
By activating soluble guanylate cyclase, riociguat increases cyclic GMP in vascular smooth muscle. This promotes vasodilation (widening of blood vessels) and can reduce pulmonary vascular resistance, helping lower the strain on the heart in pulmonary hypertension. [1]
How is riociguat taken?
The medication is taken by mouth and dosing depends on the indication and individual tolerability. Riociguat treatment typically requires careful titration and monitoring to balance effectiveness with safety, especially blood pressure. [1]
What side effects do people ask about most?
Commonly reported adverse effects include headache, dizziness, nausea, dyspepsia (indigestion), and low blood pressure (hypotension). Because riociguat can lower blood pressure, dizziness or fainting may occur, particularly when starting therapy or increasing the dose. [1]
Who should not take riociguat (and key safety checks)?
Riociguat has important safety interactions, particularly with drugs that affect the nitric oxide–cGMP pathway. It is contraindicated with PDE5 inhibitors (for example, sildenafil and tadalafil) due to the risk of excessive blood pressure lowering, and it must not be used with nitrates. Blood pressure and overall tolerability are monitored during treatment. [1]
How does riociguat compare with sildenafil or tadalafil for pulmonary hypertension?
Riociguat and PDE5 inhibitors (like sildenafil and tadalafil) both affect the cGMP pathway but through different mechanisms. Riociguat directly stimulates soluble guanylate cyclase, while PDE5 inhibitors block cGMP breakdown. They are not used together because of the risk of hypotension. Choice between them depends on the condition (PAH vs CTEPH), patient factors, and clinician guidance. [1]
Where does riociguat fit for CTEPH?
For CTEPH, riociguat is a targeted option when the disease is not fully treatable with surgery or when residual/recurrent pulmonary hypertension persists after interventions. It is used to improve pulmonary hemodynamics and symptoms in appropriate patients. [1]
What should patients know about monitoring while on riociguat?
Patients are typically monitored for blood pressure changes and symptoms of low blood pressure (such as dizziness), as well as for other tolerability issues during dose adjustments. Clinicians may also track clinical response over time. [1]
Sources
- https://www.ema.europa.eu/en/medicines/human/EPAR/Adempas